ArticleCells2019
Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells.
Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- PCOS and breast cancer risk: hormonal modulation and epidemiological trends.Reproductive health · 2026Review
- Insulin-like growth factor 1 receptor regulates breast cancer cell adhesion through beta-1 integrin.Frontiers in endocrinology · 2026Article
- Insulin-Like Growth Factor 1 Receptor Regulates Breast Cancer Cell Adhesion through Beta-1 Integrin.bioRxiv : the preprint server for biology · 2025Article
- Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm.Leukemia · 2025Article
- Investigation of the relationship between breast cancer and clinical symptoms of polycystic ovarian syndrome: a case-control study.BMC women's health · 2024Article
- A New Nonparametric Multivariate Control Scheme for Simultaneous Monitoring Changes in Location and Scale.Computational and mathematical methods in medicine · 2022Article
- Based on the Network Pharmacology to Investigate the Mechanism of Qingjie Fuzheng Granules against Colorectal Cancer.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- The crosstalk within the breast tumor microenvironment in type II diabetes: Implications for cancer disparities.Frontiers in endocrinology · 2022Review
- Microarray analysis of differentially expressed long non-coding RNAs in daidzein-treated lung cancer cells.Oncology letters · 2021Article
- MiR-186-3p attenuates tumorigenesis of cervical cancer by targeting IGF1.World journal of surgical oncology · 2021Article
- CircATP5SL promotes infantile haemangiomas progression via IGF1R regulation by targeting miR-873-5p.American journal of translational research · 2021Article
- Tumor suppressor p53 regulates insulin receptor (Oncotarget · 2020Article
- Article
- Prediction and Monitoring Method for Breast Cancer: A Case Study for Data from the University Hospital Centre of Coimbra.Cancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Insulin and insulin-like growth factor-1 (IGF1) have important roles in breast cancer development. The recent identification of nuclear insulin (INSR) and IGF1 (IGF1R) receptors provides a novel paradigm in the area of signal transduction. The fact that INSR and IGF1R can function as transcription factors, capable of binding DNA and controlling transcription, adds a new layer of biological complexity by conferring upon cell-surface receptors the ability to regulate genomic events. The present study was designed to assess the hypothesis that insulin and IGF1 pathways elicit differential effects on subcellular distribution and activation of ERK1/2 and AKT. To this end, MCF7 breast cancer-derived cell lines with specific INSR or IGF1R disruption were employed. In addition, small interfering RNA technology was used to specifically down-regulate INSR or IGF1R expression in T47D breast cancer cells. DNA affinity chromatography assays were conducted to address the specific binding of ERK1/2 and AKT to the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.